Sign up
Pharma Capital

Q BioMed says cancer pain drug will be available later this month

The Strontium Chloride 89 (SR89) injection has been approved by the FDA ..
A cancer cell

Q BioMed Inc (OTCMKTS:QBIO)  said it expects its cancer pain drug to be available later this month (October) and announced the launch of a website for  patients, doctors and caregivers.

The Strontium Chloride 89 (SR89) injection has been approved by the FDA and is a non-opioid injection to relieve bone pain in patients with painful skeletal metastases.

Clinical studies showed the combination of alternating weekly chemohormonal therapies with Strontium-89 demonstrated a prolonged progression-free and overall survival in patients.

The website is at

In the body, Strontium-89 acts in a similar way to calcium and is preferentially taken up in osteoblastic tissue selectively localizing in bone.

Q BioMed shares added 2.13% to US$3.83 each.

Why Invest In Q BioMed Inc? Read More Here

Register here to be notified of future QBIO Company articles
View full QBIO profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.